Biomarin Pharmaceutical: Pay

Biomarin Pharmaceutical paid its 5 named executives $47.3M in total in FY2025 (Dec). CEO Alexander Hardy was paid $21.9M of that.

Pay$100 in the stock at the end of FY22 → $57
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Alexander HardyPresident and CEO
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
3 years
Gregory R. Friberg, M.D.Executive Vice President, Chief Research & Development Officer
FY2025 (Dec)
FY2024 (Dec)
2 years
Brian R. MuellerExecutive Vice President, CFO
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
5 years
Cristin HubbardExecutive Vice President, Chief Commercial Officer
FY2025 (Dec)
FY2024 (Dec)
2 years
C. Greg Guyer, Ph.D.Executive Vice President, Chief Technical Officer
FY2025 (Dec)
FY2024 (Dec)Not disclosed
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
5 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 8 peers with pay on file was $16.5M. The CEO of Biomarin Pharmaceutical was paid $21.9M, 33% above the median.

  1. 1Exelixis
  2. 2Incyte
  3. 3Gilead Sciences
  4. 4Biomarin Pharmaceutical
  5. 5United Therapeutics
  6. 6Alnylam Pharmaceuticals
  7. 7Ionis Pharmaceuticals
  8. 8Regeneron Pharmaceuticals
  9. 9Neurocrine Biosciences
  10. 10BeOne Medicines Ltd. (f/k/a BeiGene, Ltd.)Not disclosed
  11. 11BiogenNot disclosed
  12. 12Jazz PharmaceuticalsNot disclosed
  13. 13Sarepta Therapeutics, Inc.Not disclosed
  14. 14Ultragenyx Pharmaceuticals Inc.Not disclosed
  15. 15Vertex Pharmaceuticals IncorporatedNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.